Details for Patent: 6,899,890

Which drugs does patent 6,899,890 protect, and when does it expire?

Patent 6,899,890 protects CLINDESSE and is included in one NDA.

This patent has twenty-two patent family members in sixteen countries.

Summary for Patent: 6,899,890

Title:	Bioadhesive drug delivery system
Abstract:	The present invention relates to a novel essentially pH neutral vaginal drug delivery system suitable for modified delivery of a therapeutically active material in the vaginal cavity. The vaginal drug delivery system comprises an essentially pH neutral emulsion having globules having two phases, an internal water soluble phase and an external water-insoluble phase or film, wherein the water-soluble interior phase contains a therapeutically active drug or drugs. One novel aspect of the vaginal drug delivery system is that the internal water soluble phase comprises an acidic buffered phase.
Inventor(s):	Kirschner; Mitchell I. (St. Louis, MO), Levinson; R. Saul (Chesterfield, MO), Riley; Thomas C. (Manchester, MO), Hermelin; Marc S. (St. Louis, MO)
Assignee:	KV Pharmaceutical Company (St. Louis, MO)
Application Number:	10/101,014
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 6,899,890
Patent Claim Types: see list of patent claims	Compound; Delivery; Composition; Dosage form; Use;

Drugs Protected by US Patent 6,899,890

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Padagis Us	CLINDESSE	clindamycin phosphate	CREAM;VAGINAL	050793-001	Nov 30, 2004		RX	Yes	Yes			Y			METHOD OF TREATING BACTERIAL VAGINOSIS

International Family Members for US Patent 6,899,890

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Argentina	039037
Australia	2002300175
Australia	2003218233
Brazil	0202767
Canada	2392473
China	101045034
China	102048689